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Abstract
A follow-up study of a large Utah family with significant linkage to chromosome 2q24 led us to identify a new febrile seizure
(FS) gene, SCN9A encoding Nav1.7. In 21 affected members, we uncovered a potential mutation in a highly conserved amino
acid, p.N641Y, in the large cytoplasmic loop between transmembrane domains I and II that was absent from 586 ethnically
matched population control chromosomes. To establish a functional role for this mutation in seizure susceptibility, we
introduced the orthologous mutation into the murine Scn9a ortholog using targeted homologous recombination.
Compared to wild-type mice, homozygous Scn9a
N641Y/N641Y knockin mice exhibit significantly reduced thresholds to
electrically induced clonic and tonic-clonic seizures, and increased corneal kindling acquisition rates. Together, these data
strongly support the SCN9A p.N641Y mutation as disease-causing in this family. To confirm the role of SCN9A in FS, we
analyzed a collection of 92 unrelated FS patients and identified additional highly conserved Nav1.7 missense variants in 5%
of the patients. After one of these children with FS later developed Dravet syndrome (severe myoclonic epilepsy of infancy),
we sequenced the SCN1A gene, a gene known to be associated with Dravet syndrome, and identified a heterozygous
frameshift mutation. Subsequent analysis of 109 Dravet syndrome patients yielded nine Nav1.7 missense variants (8% of the
patients), all in highly conserved amino acids. Six of these Dravet syndrome patients with SCN9A missense variants also
harbored either missense or splice site SCN1A mutations and three had no SCN1A mutations. This study provides evidence
for a role of SCN9A in human epilepsies, both as a cause of FS and as a partner with SCN1A mutations.
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Introduction
Febrile seizures (FS) are the most common seizure disorder of
early childhood, and exhibit a prevalence of 2–5% in European
and North American children [1]. Large FS families reported in
the clinical literature support a genetic etiology for febrile seizures,
as does the 31% incidence of FS in first-degree relatives [2].
Individuals who experience FS have a 2–9% chance of developing
afebrile seizures later in life [1] and this incidence is four times
higher if there is a family history of FS [3]. These later-onset
epileptic phenomena include generalized convulsive, as well as
simple and complex partial seizures that can be resistant to
currently available anticonvulsant therapy [1]. Notably, FS occur
in up to 75% of children with the catastrophic early-onset epilepsy
disorder of ‘severe myoclonic epilepsy of infancy’ or Dravet
syndrome. In Dravet syndrome, a normally developing child at 2
to12 months of age has convulsive seizures that are prolonged and
indiscriminately lateralized. In the second or third year of life,
these children have frequent myoclonic, partial and atypical
absences as well. While the myoclonic attacks disappear after 4–7
years, these children continue to have generalized tonic-clonic,
clonic and complex partial seizures with common episodes of
nonconvulsive status epilepticus [1].
The hypothesis that alleles predisposing to FS may be found in
Dravet syndrome patients led Claes et al. to find a high frequency
of SCN1A gene mutations in patients with Dravet syndrome
[1,4,5]. Since then, others have proposed a complex genetic
etiology for Dravet syndrome. This is based on the observation
that over 50% of Dravet syndrome patients have de novo SCN1A
mutations yet belong to families with a history of FS [6–9]. In
addition, identical SCN1A missense or truncation mutations are
associated with widely different seizure severities, including
intractable seizures of Dravet syndrome, comparatively benign
FS, and even asymptomatic family members in some cases [10–
12]. However, definitive genetic evidence supporting a multifac-
torial hypothesis of Dravet syndrome is lacking [8,13].
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(cM) region on chromosome 2q24 in a large Utah kindred (K4425)
with FS before the age of six years in 21 individuals, including 10
individuals with subsequent afebrile seizures [14]. This region
contains five sodium channel a subunit genes including SCN1A,
SCN2A and SCN3A that share over 85% identity and are highly
expressed in brain [15]. SCN1A is commonly mutated in Dravet
syndrome and mutations in either SCN2A or SCN1A are associated
with the generalized (genetic) epilepsy febrile seizure plus (GEFS+)
syndrome [4,16–18]. Mutations in SCN2A have also been reported
in patients with benign familial neonatal-infantile seizures and a
single SCN3A mutation has recently been identified in a pediatric
patient with partial epilepsy [19,20]. Clearly, this genomic region
contains several important genes that impact seizure susceptibility
in children.
Results
Identification of a Familial Mutation in the SCN9A Sodium
Channel Alpha Subunit Gene
Sequence analysis of whole blood DNA from affected
individuals or a monosomal hybrid cell line DNA containing the
disease chromosome from patient III-26 in K4425 did not reveal
any disease-causing variants within the coding region or exon-
intron junctions in either SCN1A, SCN2A, SCN3A, SCN7A, KCNH7
or SLC4A10, all of which are candidate genes within the linkage
region. Deletion/duplication analysis of the SCN1A coding region
using the multiplex amplicon quantification method [21] in two
severely affected K4425 individuals (III-14 and IV-9) was also
negative. Furthermore, copy number variation (CNV) analysis of
the distal 10 Mb (84%) K4425 linkage region, including SCN1A,
SCN2A, SCN3A, SCN7A and SCN9A, ascertained by using the
Agilent array comparative genomic hybridization platform, found
no shared CNV between two affected K4425 individuals, III-12
and IV-9 (data not shown). DNA sequencing of five recently
identified 59 UTR exons and seven cis-conserved noncoding
sequences that overlap two additional 59UTR exons of SCN1A
[22,23] revealed no variants in K4425 III-14 when compared to
the reference sequence. Despite extensive analysis of these
candidate genes in the linkage region, we were unable to find
any disease-causing mutations.
SCN9A, which also resides within the K4425 critical genetic
interval [14], is expressed primarily in neurons of the dorsal root
ganglia and has preliminarily been classified as a peripheral
nervous system channel [15]. This expression pattern is consistent
with the phenotypes of three inherited disorders that are caused by
recently described disease-associated SCN9A mutations: autosomal
dominant primary erythermalgia (PE) and paroxysmal extreme
pain disorder (PEPD), and autosomal recessive channelopathy
associated insensitivity to pain (CIP) [24–26]. However, early
SCN9A gene cloning papers [27] showed expression of NaV1.7 in
brain of rodents and more recent expression analysis experiments
have confirmed these observations [28]. The GEO (GDS423 and
GDS1085, for example) and Unigene (Hs.439145) databases also
contain experimental evidence that SCN9A is expressed in brain.
We therefore sequenced all 26 coding exons of SCN9A (NM
002977, NP 002968) to test the hypothesis that it harbors the
disease-causing allele in FS affected individuals of K4425. Analysis
of the large intracellular loop between domains I and II revealed a
heterozygous highly conserved missense change (p.N641Y,
c.1921A.T) that cosegregates with all 21 affected K4425
individuals, in addition to a single non-penetrant individual (IV-
8) (Figure 1A and 1B). A non-penetrant individual is not
unexpected as they are commonly seen in autosomal dominant
diseases and are well documented in FS pedigrees. Inherited
autosomal dominant forms of FS have a reduced penetrance of
60–80% [29–31], meaning that 20–40% of individuals with
mutations who belong to FS families will not experience seizures.
The penetrance of FS in K4425 is actually rather high at
approximately 95%. The N641Y variant was absent from 586
chromosomes from an ethnically matched population of unrelated
individuals, providing supporting evidence for this nucleotide
change being the disease-causing mutation in this family.
Broad Clinical Spectrum of Seizures in K4425 Individuals
with SCN9A-N641Y
A broad spectrum of seizure manifestations is observed in
K4425 family members who harbor the p.N641Y mutation [14].
Illustrating the milder end of the continuum are 11 individuals
from K4425 who experienced only FS before six years of age. The
remaining ten of the 21 affected individuals in K4425 experienced
FS before six years of age followed by later afebrile seizures. In
eight of these ten, the seizures remitted by the age of 16. Finally,
two individuals, III-14 and IV-9, developed intractable epilepsy.
Patient III-14 experienced her first simple FS at age 1.5 years
followed before age five by several non-febrile convulsions and at
least one prolonged generalized convulsive seizure lasting at least
45 minutes. After age five, she had occasional complex-partial
seizures and was diagnosed with left mesial temporal sclerosis at 22
years of age. At about one year of age, patient IV-9 began having
frequent simple FS without focal onset and never lasting more
than 2 minutes. However, he had as many as 60 such seizures until
about 4–5 years of age. Afebrile generalized convulsive seizures
began at about 6 years of age followed closely by very frequent
typical absence seizures. He has never had prolonged convulsions,
hemiclonic or secondarily generalized seizures, drop attacks,
myoclonic or astatic seizures, or ‘‘atypical absence’’ episodes,
and there has been no developmental regression. Now 11 years of
Author Summary
Febrile seizures are the most common seizure disorder of
early childhood, and exhibit a prevalence of 2%–5% in
European and North American children. While the genetic
basis of febrile seizures is well-documented, efforts to
uncover these genes have yielded only a few genes in a
small proportion of cases. In a genomic region on human
chromosome 2 known to harbor the febrile seizure SCN1A
sodium channel gene, we now report a disease-causing
mutation in the adjacent gene, SCN9A (Nav1.7), in a large
family with febrile seizures. We introduced the family
mutation (N641Y) into the orthologous mouse gene to
create a knockin mouse model, and tested seizure
susceptibility in these mice. Compared to wild-type mice,
our Scn9a knockin mice have a significantly lower
threshold to electrically induced seizures and experience
seizures at a significantly faster rate with repeated
subthreshold stimulation. We also report novel missense
SCN9A mutations in unrelated febrile seizure patients.
Furthermore, we show that a subset of patients with the
catastrophic early-onset Dravet syndrome who commonly
have mutations in SCN1A also harbor mutations in SCN9A.
This finding is important as it demonstrates for the first
time mutational evidence for a modifying digenic mech-
anism of human epilepsy. For infants with Dravet
syndrome, a genetic diagnosis will be of immediate
benefit to guide therapeutics away from the sodium
channel blocking class of anticonvulsant drugs that
exacerbate seizures but are often the first administered.
SCN9A in Febrile Seizures and Dravet Syndrome
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stimulator (placed at 8 years of age). Electroencephalography
demonstrated very frequent frontally predominant generalized 3
to 5 Hz spike and slow wave and polyspike and wave discharges
(data not shown). In both of these severely affected K4425
patients, we ruled out additional modifying mutations in four other
known FS susceptibility genes, SCN1A, SCN2A, SCN1B and
GABRG2, by sequencing the coding and splice site regions.
Reduced Electrical Seizure Thresholds and Increased
Corneal Kindling Acquisition Rates in Scn9a-N641Y
Knockin Mice
To confirm the role of SCN9A in seizure susceptibility in K4425,
we evaluated knockin mice to determine whether the p.N641Y
mutation confers a reduced threshold to electrically induced
seizures and an enhanced susceptibility to stimulus evoked
kindling. Targeted knockin mice were made using previously
described methods [32,33]. Briefly, the following changes were
introduced into the wild-type Scn9a (Figure 2A): the p.N641Y
mutation into exon 11, the ACN positive selection vector into
intron 10, and the negative TK selection vector into intron 12
(Figure 2B). Embryonic stem cells evaluated by PCR and Southern
blotting techniques were successfully targeted by homologous
recombination (Figure 2D). During spermatogenesis, a single male
chimera self-excised the positive selection vector (Figure 2C) and at
the appropriate age, was mated to a C57BL/6J (B6) female.
Genotype analysis reveal that N1F2 offspring had the p.N641Y
mutation (Figure 2E) and a single remaining loxP site (Figure 2F).
At birth, mutant N1F2 mice showed no significant deviation from
Mendelian ratios. The wild-type (B6;129-Scn9a
+/+):heterozygote
(B6;129-Scn9a
N641Y/+):homozygote (B6;129-Scn9a
N641Y/N641Y)
birth rate is 105:182:101 (p=0.84). No body size difference was
observed among the genotypes for either gender and no premature
postnatal death occurred up to P90.
N1F2 P25–P47 Scn9a knockin littermate mice were subjected to
corneal electrical stimulation using the staircase method to either a
clonic seizure endpoint or tonic hindlimb extension seizure
endpoint that depolarizes the forebrain and hindbrain regions,
respectively [34]. Convulsive current (CC) levels at which 50% of
mice are predicted to seize and the corresponding 95% confidence
intervals were calculated for each seizure endpoint. Homozygous
B6;129- Scn9a
N641Y/N641Y knockin mice exhibited significantly
reduced thresholds to minimal clonic (Figure 3A) and minimal
tonic hindlimb extension (Figure 3B) seizures relative to their wild-
type littermates. Figure 3A shows convulsive current curves
generated by testing male B6;129-Scn9a
N641Y/N641Y, B6;129-
Scn9a
N641Y/+ and B6;129-Scn9a
+/+ mice to minimal clonic
electroconvulsive seizures. The CC50 value for this type of seizure
is significantly lower for B6;129-Scn9a
N641Y/N641Y (CC50, 7.1 mA)
mice compared to B6;129-Scn9a
N641Y/+ (CC50, 7.83 mA) and
B6;129-Scn9a
+/+ (CC50, 8.38 mA) mice; B6;129-Scn9a
N641Y/N641Y
vs B6;129-Scn9a
N641Y/+ p=0.008; B6;129-Scn9a
N641Y/N641Y vs
B6;129-Scn9a
+/+ p=0.001; B6;129-Scn9a
N641Y/+ vs B6;129-
Scn9a
+/+ p=0.093; n=30–68. Figure 3B shows convulsive current
curves generated by testing female B6;129-Scn9a
N641Y/N641Y,
B6;129-Scn9a
N641Y/+ and B6;129-Scn9a
+/+ mice to minimal tonic
hindlimb extension electroconvulsive seizures. Female B6;129-
Scn9a
N641Y/N641Y (CC50, 9.44 mA) mice exhibited a significantly
lower CC50 value compared to heterozygous B6;129-Scn9a
N641Y/+
(CC50,11.16 mA)andwild-typeB6;129-Scn9a
+/+(CC50,11.50 mA)
mice; B6;129-Scn9a
N641Y/N641Y vs B6;129-Scn9a
N641Y/+ p,0.001;
B6;129-Scn9a
N641Y/N641Y vs B6;129-Scn9a
+/+ p,0.001; B6;129-
Scn9a
N641Y/+ vs B6;129-Scn9a
+/+ p=0.227; n=26–49.
In a separate test to evaluate seizure susceptibility, the rate of
kindling acquisition was evaluated in Scn9a-N641Y knockin mice.
Male N5F2 P69–P164 Scn9a knockin littermate mice were
stimulated twice daily with a subthreshold 3mA corneal stimula-
tion for 3 seconds until they reached a stably kindled state, defined
Figure 1. Pedigree of family K4425 with an SCN9A mutation. (A) Segregation of the Nav1.7 p.N641Y mutation and phenotypic findings of
K4425; fs, febrile seizures; afs, afebrile seizures; +, wild-type; m, p.N641Y mutation. (B) Sequence chromatogram of genomic DNA from individual III-1
shows a heterozygous c1921A.T (p.N641Y) mutation in exon 11 of SCN9A.
doi:10.1371/journal.pgen.1000649.g001
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4–5) [35]. Homozygous B6.129- Scn9a
N641Y/N641Y knockin mice
exhibited a significantly faster kindling acquisition rate relative to
their wild-type littermates (Figure 4A). A significantly lower
number of stimulations (Figure 4B) was required to reach the first
fully generalized (5.6360.92, 6.9360.89, 9.8960.93) and fourth
consecutive generalized (11.1361.2, 12.6460.86, 14.5660.88)
seizure for B6.129-Scn9a
N641Y/N641Y mice compared to B6.129-
Scn9a
N641Y/+ and B6;129-Scn9a
+/+ mice, respectively.
Two homozygous mutant female mice were video-monitored
continuously from P33–P47 and three homozygous mutant male
mice were continuously video-monitored from P27–P50 during
the 12-hour daylight cycle. We did not observe any behavior, such
as rearing and falling or forelimb or hindlimb clonus, consistent
Figure 2. Generation of Scn9a-N641Y knockin mice. Schematic representation of the (A) wild-type allele, (B) targeting construct introduced into
embryonic stem (ES) cells. Numbered boxes denote exons; *, p.N641Y missense change introduced into exon 11; PCRa and PCRb, primers used to
screen ES cell DNA for homologous recombination; S and probe, denotes SspI sites and probe used in genomic Southern blot of ES cells; ACN
cassette, Cre-recombinase gene (Cre) driven by the testes-specific promoter from the angiotensin-converting enzyme gene (tACE); Cre is linked to the
Neo
r selectable marker driven by the mouse RNA polymerase II large subunit gene (polII); the entire cassette is flanked by 34 bp loxP sites oriented in
parallel. TK, HSV-TK gene for negative selection of ES cells. (C) following Cre-mediated self-excision in the chimeric mouse germline, a single loxP site
and the point mutation remain. (D) Southern blot of three SspI cut ES cell clones followed by hybridization of probe yields an 8.4 kb endogenous
band and a 7.2 kb targeted band (horizontal arrows); vertical arrow denotes clone used to make mouse. (E) LightScanner normalized melting peaks
used to genotype SCN9A
+/+, SCN9A
N641Y/+, and SCN9A
N641Y/N641Y mice. (F) PCR used to verify self-excision of the ACN cassette. Amplicons generated
by primers flanking remaining 34 bp loxP site in intron 10 yield distinct SCN9A
+/+ (left), SCN9A
N641Y/+ (center), and SCN9A
N641Y/N641Y (right, denoted by
arrow) bands on 2% agarose.
doi:10.1371/journal.pgen.1000649.g002
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Increased ectopic expression of neuropeptide Y in hippocampal
dentate granule cell mossy fibers typically indicates spontaneous
generalized seizure activity. Increased NPY expression was not
seen in P30, P60 and P90 N1F2 B6;129-Scn9a
N641Y/N641Y or N1F2
B6;129-Scn9a
N641Y/+ mice (data not shown). Taken together, these
data suggest that Scn9a-N641Y knockin mice did not exhibit
spontaneous seizures. It is not unexpected that our mouse model of
human FS does not exhibit spontaneous seizures because patients
with this mutation require hyperthermia for seizures to manifest.
Figure 3. Reduced electroconvulsive seizure thresholds of Scn9a knockin mice compared to wild-type littermate controls. Convulsive
current curves generated by testing (A) male B6;129-Scn9a
N641Y/N641Y, B6;129-Scn9a
N641Y/+, and B6;129-Scn9a
+/+ mice to minimal clonus
electroconvulsive seizures (B6;129-Scn9a
N641Y/N641Y vs B6;129-Scn9a
N641Y/+ p=0.008; B6;129-Scn9a
N641Y/N641Y vs B6;129-Scn9a
+/+ p=0.001; B6;129-
Scn9a
N641Y/+ vs B6;129-Scn9a
+/+ p=0.093) and (B) female B6;129-Scn9a
N641Y/N641Y, B6;129-Scn9a
N641Y/+, and B6;129-Scn9a
+/+ mice to minimal tonic
hindlimb extension electroconvulsive seizures (B6;129-Scn9a
N641Y/N641Y vs B6;129-Scn9a
N641Y/+ p,0.001; B6;129-Scn9a
N641Y/N641Y vs B6;129-Scn9a
+/+
p,0.001; B6;129-Scn9a
N641Y/+ vs B6;129-Scn9a
+/+ p=0.227). Convulsive current data are expressed in terms of 1-seizure probability (1-Pseizure) for a
given stimulus (mA). Individual data points shown for homozygote (closed square), heterozygote (x), and wild-type (closed circle) mice are used to
construct curves indicated by black solid, red dashed, and blue dotted lines, respectively.
doi:10.1371/journal.pgen.1000649.g003
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Patients
To further assess the role of Nav1.7 in FS patients, we then
analyzed SCN9A in a panel of 92 unrelated patients with childhood
seizures occurring in the setting of a febrile illness, either with or
without a family history of seizures. We identified 4 additional
missense variants in our 90 Caucasian samples and 1 variant in
our 2 Hispanic samples (Figure 5A, Table 1). p.P149Q and
p.K655R were not found in at least 562 ethnically matched
Caucasian population control chromosomes, while p.S490N and
p.I739V were found only once in at least 562 ethnically matched
Caucasian population control chromosomes. For all four Cauca-
sian mutations, Fisher’s exact two-tailed test yielded p=0.03
(4/180 unrelated FS chromosomes and 2/562 population control
chromosomes). The single Hispanic variant p.I62V was not found
in 276 ethnically matched Hispanic control chromosomes (p=0.01
for 1/4 FS chromosomes and 0/276 population control
chromosomes, Fisher’s exact two-tailed test). All five seizure-
associated Nav1.7 variants reported here occur in codons that are
highly conserved across species (Figure 5B). To rule out the role of
SCN1A in FS susceptibility in these 5 FS patients with SCN9A
variants, we sequenced the entire coding and splice site regions of
SCN1A and did not find any potential disease-causing amino acid
variations.
A Role for SCN9A in Dravet Syndrome
During the course of our studies on unrelated FS patients, the
diagnosis of one patient #34302 progressed from atypical FS to
Dravet syndrome. Beginning at five months of age, this Caucasian
patient experienced multiple generalized clonic seizures that were
predominantly afebrile, then progressed to frequent episodes of
status epilepticus and prolonged complex partial seizures by 16
months. Now 5 years old, this patient continues to have mixed
seizures (including myoclonic and astatic seizures) in spite of
resolute therapeutic intervention. Sequencing of SCN9A yielded a
p.L1123F missense variant found only once in 1736 ethnically
matched population control chromosomes (Fisher’s exact p-
value=0.0023; Figure 6, Table 1). Segregation analysis showed
that the SCN9A p.L1123F variant was inherited from the
asymptomatic mother with a reported extended family history of
seizures. Subsequent sequencing of the SCN1A gene (Swiss-Prot
P35498) known to cause Dravet syndrome uncovered a hetero-
zygous frameshift mutation (c.2675delA, p.N892fsX2) in the
intracellular loop between DIIS4 and DIIS5 (Figure 6, Table 1).
The SCN1A frameshift was de novo and misinheritance was ruled
out by testing 31 polymorphic microsatellite markers (data not
shown).
The finding of variants in both SCN1A and SCN9A in a single
patient led us to investigate whether additional disease-associated
alleles in SCN9A contribute to Dravet syndrome. In an analysis of a
cohort of 109 Dravet syndrome patients, 50% of whom had
SCN1A mutations, we found 8 additional SCN9A variants within
the transmembrane domains and intracellular and extracellular
loops of Nav1.7 in 9 patients (Table 1). The missense variants
p.C699Y, K655R and p.E1160Q were not found in at least 576
control chromosomes and the remaining 5 missense variants were
found in 0.3% of at least 576 control chromosomes (p=0.004 for
9/218 Dravet syndrome cases and 5/576 population controls,
Fisher’s exact two-tailed test). Of the 9 Dravet syndrome patients
with SCN9A variants, six harbor either splice site or missense
mutations in SCN1A (Table 1, Figure 5). Two of these SCN9A
variants (p.K655R and p.I739V) are also found in our FS patients.
In the three remaining Dravet syndrome patients without SCN1A
mutations, additional proconvulsive genes that act in concert with
SCN9A may yet be uncovered. Protein secondary structure
prediction using Consensus Data Mining [36] found coil to a-
helix (p.I684M), a-helix to coil (p.I739V, p.L1123F, p.L1267V)
and ß-sheet to coil (p.E1160Q) alterations.
An alternate statistical approach is to examine the mutational
burden of SCN9A, comparing rare (,1%) variants identified by
mutational analysis of the entire coding region in all FS and Dravet
syndrome populations combined versus the entire coding region in
population control individuals. Analysis of the coding and splice site
regions of SCN9A was performed only in a subset of our control
panel consisting of 95 healthy individuals from the Utah CEPH
Figure 4. Increased corneal kindling acquisition rates of Scn9a
knockin mice compared to wild-type littermate controls. Male
N5F2 mice separated by genotype (n=8–15) were stimulated with
corneal electrodes twice daily until four consecutive Racine Stage 4 or 5
secondarily generalized seizures were elicited. The effect of Scn9a-N641Y
on kindling acquisition is shown in (A) for B6.129-Scn9a
+/+, B6.129-
Scn9a
N641Y/+, and B6.129-Scn9a
N641Y/N641Y mice; results are expressed as
the average seizure score per genotype observed after each stimulation.
(B) The number of stimulations required to reach the first fully
generalized Racine Stage 4–5 seizure, regraphed with p-values from
the data in (A), is 9.8960.93 (B6.129-Scn9a
+/+, clear bar), 5.6360.92
(B6.129-Scn9a
N641Y/N641Y, black bar), and 6.9360.89 (B6.129-Scn9a
N641Y/+,
pink bar), left panel; the number of stimulations required to reach a fully
kindled mouse defined as four consecutive Racine Stage 4–5 seizures,
regraphed with p-values from the data in (A), is 14.5660.88 (B6.129-
Scn9a
+/+, clear bar), 11.1361.2 (B6.129-Scn9a
N641Y/N641Y, black bar),
12.6460.86 (B6.129-Scn9a
N641Y/+, pink bar), right panel.
doi:10.1371/journal.pgen.1000649.g004
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p.D1971V). Our affected population in which the entire gene was
analyzed consisted of 93 FS including a single person from the
family K4425 plus 110 Dravet syndrome patients, including the
initial patient #34302. This approach yielded p,0.10, Fisher’s
exact one-tailed test and p,0.07, Fisher’s Exact-Boschloo with the
Berger & Boos correction [37] (3/190 Utah CEPH chromosomes
and 16/406 FS and Dravet syndrome unrelated seizure cases
combined).
Discussion
In this study, we have shown that a mutation in a highly
conserved amino acid residue of the SCN9A sodium channel
alpha subunit is associated with a wide clinical spectrum of
seizure phenotypes in a single large family. These phenotypes
include simple FS, self-limited afebrile seizures, and temporal
lobe epilepsy. The SCN9A-N641Y segregating mutation in our
large K4425 FS family, and the significantly reduced seizure
Figure 5. SCN9A is mutated in multiple patients with febrile seizures (FS) and Dravet syndrome. (A) Phenotypic profile and secondary
structure locations of all variants found in SCN9A. Red text, variants in FS patients; blue text, variants in Dravet syndrome patients; black text, variants
in both phenotypes; *variants also found in controls. (B) Amino acids from the UCSC genome browser (http://genome.ucsc.edu/) showing
conservation across 8 species for FS and Dravet syndrome variants (red) found in SCN9A. The human Nav1.7 protein shares identity of 97% to rhesus,
92% to rat, 92% to mouse, 94% to cow, 94% to dog, 93% to rabbit, and 75% to chicken.
doi:10.1371/journal.pgen.1000649.g005
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conferred uniquely by the same mutation introduced into the
Scn9a-N641Y knockin mouse, provide strong evidence that
SCN9A has a role in central excitability and is disease-causing
in this family.
In addition, we find supporting evidence for a multifactorial
etiology of Dravet syndrome by uncovering concurrent variants in
both SCN9A and SCN1A in a subset of our patients. Our findings of
numerous variants in separate FS and Dravet syndrome cohorts
are statistically significant (p,0.05) when the frequency of the
combined specific altered residues found in patients is compared to
those same residues in controls, but not statistically significant
when all variants found in FS and Dravet syndrome patients are
compared to all variants found in controls. While our findings
provide highly suggestive evidence of the role of SCN9A in FS and
Dravet syndrome, replication in multiple cohorts, combined with
functional studies, is needed to confirm a hyperexcitable role of
SCN9A in unrelated epilepsy patients. The multifactorial etiology
of Dravet syndrome proposed by many investigators suggests that
it is very likely that genes responsible for Dravet syndrome will far
outnumber SCN1A and SCN9A.
The corneal stimulation paradigm is a reliable and reproducible
measure for inducing seizures to test the efficacy of anticonvulsant
drugs [34]. A Kcnq3 and two separate Kcnq2 mouse models as well
as the models for the Wolf-Hirschhorn deletion syndrome have
helped to validate the corneal stimulation paradigm as a robust
seizure susceptibility test [33,38,39]. Here, we show that
homozygous knockin Scn9a
N641Y/N641Y mice are significantly more
susceptible than wild-type mice to seizures that activate either the
forebrain or hindbrain. Both the clonic and tonic-clonic
generalized seizures characteristic of FS patients are induced by
lower stimulation currents in mice that harbor the p.N641Y
mutation in Scn9a. In the corneal kindling model, repeated
application of an initially subconvulsive electrical stimulus results
in progressive escalation of the stimulus-induced epileptic activity,
culminating in a partial seizure that secondarily generalizes [35].
This model of partial epilepsy successfully validated a first-in-class
neurotherapeutic agent based on galanin for treating pharma-
coresistant epilepsy [40] and differentiated knockin mutations
known to cause childhood epilepsy. Indeed, mutations in the Kcnq2
and Kcnq3 subunits that underlie M-current channels were recently
shown to significantly increase the rate of corneal kindling [41].
Our model adds to the growing list of other specific human
epilepsy knockin mice, including the Gabrg2 [42], Kcnq2 [33], Kcnq3
[33], Scn1a [43] and Chrna4 [44] mice, to report a clear-cut
genotype to phenotype seizure susceptibility.
In multiple published studies, some Dravet syndrome patients
inherit SCN1A mutations from asymptomatic or mildly affected
parents, making multiple mutations in this syndrome a likely
finding [7,11,12]. Furthermore, modifying alleles may preferen-
tially be found in Dravet syndrome patients with SCN1A
mutations that are less deleterious when compared to complete
heterozygous loss of function mutations. This is indeed that case
for the majority of our Dravet syndrome patients with SCN9A
variants. Six out of seven of our Dravet syndrome patients with
SCN9A variants harbor either missense or splice site mutations in
SCN1A while a sizable portion of published SCN1A mutations are
predicted to lead to truncated proteins [8]. Our results support
the idea that some SCN9A variants when found alone might be
asymptomatic or cause infrequent febrile seizures due to
incomplete penetrance and variable expressivity, but likely
contribute in a multifactorial fashion to Dravet syndrome.
Indeed, a recent finding of almost 100 unique missense SCN1A
mutations challenges the previously held notion that haploinsuffi-
cient SCN1A mutations alone are responsible for Dravet
syndrome because many of these missense mutations likely confer
only partial, rather than complete, heterozygous loss of function
[22]. Our results now suggest that Dravet syndrome may be
Table 1. Overview of patients with SCN9A variants and their corresponding SCN1A mutation.
Sample Phenotype SCN9A (Inheritance) SCN1A (Inheritance)
K4425 (n=21) FS, AFS, TLE p.N641Y/c.1921A.T (AD) none
34351 FS p.I62V/c.184A.G (n.a.) none
40095 FS p.P149Q/c.446C.A (n.a.) none
EPD279.1 complex FS p.S490N*/c.1469G.A (n.a.) none
34447 FS, GSW, IGE p.K655R/c.1964A.G (n.a.) none
33418 FS, IGE p.I739V*/c.2215A.G (P) none
EP272.01 SMEB-MA p.I228M*/c.684C.G (M) p.V982L/c.2944G.C( de novo)
EPD232.1 Dravet p.E519K*/c.1555G.A (M) none
EP268.01 Dravet p.K655R/c.1964A.G (P) p.M934I/c.2802G.A( de novo)
EPD72.1 Dravet p.K655R/c.1964A.G (n.a.) none
EP64.03 Dravet p.I684M*/c.2052A.G (M) c.4338+1G.A( de novo)
EP260.01 Dravet p.C699Y/c.2096G.A (P) c.1029-1G.A( de novo)
EP263.01 SMEB-MA p.I739V*/c.2215A.G (P) p.A1326D/c.3977C.A( de novo)
34302 Dravet p.L1123F*/c.3369G.T (M) p.N892fsX2/c.2675delA (de novo)
EPD189.1 Dravet p.E1160Q/c.3478G.C (M) none
EPD227.1 Dravet p.L1267V*/c.3799C.G (n.a.) c.3706-2A.G (n.a.)
*In ,0.3% controls. FS, febrile seizures; AFS, afebrile seizures; TLE, temporal lobe epilepsy; GSW, generalized spike wave; IGE, idiopathic generalized epilepsy; SMEB-MA,
Dravet syndrome without myoclonic seizures and ataxia.
Reference sequences used are: SCN9A (NP 002968) and SCN1A (Swiss-Prot P35498).
AD, autosomal dominant; P, paternal; M, maternal; n.a., parents not available.
doi:10.1371/journal.pgen.1000649.t001
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Huntington’s disease and cystic fibrosis [45]. Additional new
functional data that examines the two gene mutations will be
required to test if the ‘‘two-hit’’ hypothesis is valid in certain
Dravet syndrome patients.
None of our FS or Dravet syndrome variants overlaps with the
SCN9A disease-associated changes found in the extreme pain or
insensitivity to pain disorders [24–26,46]. Furthermore, in all
published studies of PE, PEPD and CIP, an increased incidence of
seizures is not reported in patients with SCN9A mutations [24–26].
After follow-up questioning, none of the 21 affected members of
K4425 reported the easily recognized extreme pain phenotypes
associated with some SCN9A missense mutations. PEPD is often
misdiagnosed as epilepsy because tonic non-epileptic seizures are a
particular feature in infancy and early childhood. However the
‘‘slow-flat-slow’’ ictal EEG pattern associated with profound
syncope in PEPD patients is clearly not epileptiform, whereas
EEGs in K4425 patients are epileptiform [14,47]. Another
distinguishing feature is that PEPD attacks are provoked by
physical stimulation and not by hyperthermia as seen in FS.
The notion that dysfunction in the same ion channel can be
associated in distinct paroxysmal phenotypes is already known for
SCN9A. In 17 of 18 patients with SCN9A missense mutations
published to date, the rectal, ocular and mandibular pain seen in
PEPD does not overlap with the severe burning hand and foot
pain characteristic of PE [48]. We now extend the tissue specificity
of paroxysmal Nav1.7 malfunction to the central nervous system.
Additional support for discrete phenotypes resulting from the same
ion channel protein comes from the identification of SCN1A
mutations in either epilepsy or familial hemiplegic migraine [49],
and CACNA1A mutations in familial hemiplegic migraine, episodic
ataxia and spinocerebellar ataxia [50]. Experimentally, the Nav1.7
p.L858H PE mutation causes hyperexcitable sensory neurons and
hypoexcitable sympathetic neurons, and these opposing electrical
properties are a result of neuron specific physiologically coupled
proteins [51]. A unique complement of Nav1.7 interacting proteins
or second messenger pathways in the central nervous system may
also explain how the same gene previously implicated with
peripheral pain can also be associated with an epilepsy phenotype,
but this hypothesis will require further study.
Figure 6. Utah Dravet syndrome patient #34302 harbors mutations in both SCN9A and SCN1A. Sequence chromatograms of wild-type
(top panel) and mutant (middle panel) clones of SCN1A exon 15 reveals a frameshift mutation p.N892fsX2 (c.2675delA); sequence chromatogram of
genomic DNA shows a heterozygous p.L1123F (c.3369G.T) in exon 17 of SCN9A exon (bottom panel).
doi:10.1371/journal.pgen.1000649.g006
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Patient Ascertainment
Institutional Review Board informed consent was obtained from
all participants. FS patients in our sample experienced at least one
seizure in a setting of fever, concurrent with a visit to the
emergency room where the FS diagnosis was first made by the
attending physician. The majority, but not all, patients had follow-
up care by our epilepsy clinic at the University of Utah, so
recurrent FS and the presence of afebrile seizures are known for
most patients. Dravet syndrome patients are ascertained by
neurologists who follow ILAE clinical criteria and are located
primarily throughout Europe.
Mutation Detection of Patient and Control DNA Samples
DNA isolated from blood (Puregene) was sequenced using
primers designed outside the exons of SCN9A followed by standard
ABI technology at the University of Utah Sequencing Core
Facility. Sequence was analyzed using the Sequencher program
(Gene Codes Corporation). Mutation detection of control and
disease cohorts was done either by sequencing or by the
LightScanner system using the manufacturer’s recommendations
(Idaho Technology). Copy number variation analysis comparing
two affected individuals and their respective unaffected parent was
performed using the Agilent array comparative genomic hybrid-
ization platform. We hybridized 4644 K arrays at an average
resolution of 3 probes per kB, including 5% exonic probes and
56% intragenic probes, in accordance with the manufacturer’s
specifications. Deletion-duplication analysis was performed using
the multiplex amplicon quantification method [21]. Fisher’s exact
two-tailed test was performed to assess significance.
Generation of B6.129- Scn9a Knockin Mice
Wild-type clones of Scn9A were isolated from a mouse BAC
clone library (CHORI) and subcloned into pUC18. The p.N641Y
point mutation in exon 11 was introduced using the QuickChange
II XL system (Stratagene). The ACN cassette was cloned into a
PmlI site in intron 10 and this construct was cloned into a
thymidine kinase (TK) vector [32]. Within the ACN cassette the
neomycin (neo) gene driven by the mouse RNA polymerase II
promoter (polII) confers positive selection and the TK gene confers
negative selection of ES cells. The targeting vector was linearized
with NotI, introduced by electroporation into R1 ES cells [52] and
selected for resistance to G418 and FIAU. DNA from 104 colonies
was isolated and screened for homologous recombination by PCR
using primers designed outside the construct and within the ACN
cassette. Three positives were sequenced to determine the
presence of the mutation. Southern blot analysis was done on
three SspI cut ES cell clones to verify presence and orientation of
endogenous and targeted alleles. Hybridization of
32P-labelled
probe in intron 11 yields an 8.4 kb endogenous band and a 7.2 kb
targeted band in mutation positive sample. ES cells from this single
targeted clone were aggregated with C57BL/6-derived morulae,
and implanted into a pseudopregnant C57BL-6 female. During
chimeric male spermatogenesis, Cre recombinase (Cre) driven by
the murine angiotensin-converting enzyme promoter, tACE,
confers loxP-mediated excision of the ACN cassette to yield a
single remaining loxP site. Chimeric progeny were identified by
coat color and nine males were crossed to C57BL/6J (Jackson labs)
females for the generation of F1 offspring. F1 offspring were
intercrossed to generate F2 experimental animals.
To detect Cre-mediated self-excision of the ACN cassette and
presence of the mutation, genomic DNA obtained from tail
biopsies of F1 and F2 animals was analyzed. PCR primers were
used to asymmetrically amplify a product containing the mutated
base pair. An unlabeled oligonucleotide probe complimentary to
the excess strand in the region surrounding the mutated base was
included and the reaction melted using a LightScanner (Idaho
Technology) instrument. Melt curves were analyzed using Light-
Scanner software (Idaho Technology) and distinct melt profiles
were recognizable for each genotype. To verify self-excision,
primers surrounding the remaining loxP site were used to amplify
PCR products that were electrophoresed on a 2% agarose gel. The
presence of a single loxP site verifies self-excision. Mouse colonies
were maintained and used experimentally at the University of
Utah in accordance with Institutional Animal Care and Use
Committee approved protocols.
Evaluation of Electrical Thresholds and Corneal Kindling
Acquisition Rates in Scn9a
+/+, Scn9a
+/N641Y, and
Scn9a
N641Y/N641Y Littermate Mice
For baseline seizure threshold estimates, seizure incidence was
determined at several different stimulus intensities according to the
staircase estimation procedure [53]. Convulsive current (CC)
curves were then constructed from these data by Probit analysis,
and CC1–99 values statistical comparisons were calculated using
Minitab 13 (State College, PA, U.S.A.) and p values are calculated
for full CC curve comparisons. CC curves for knockin mice were
compared with those of littermate wild-type mice and seizure
thresholds were considered significantly different at p,0.05. Two
different stimulation protocols were used in an effort to
differentiate the effects of genotype on forebrain (minimal clonic)
and hindbrain (minimal tonic hindlimb extension) seizure
thresholds. Seizures were induced at varying intensities using a
60-Hz, 0.2-ms sinusoidal current pulse with a stimulator previously
described [53]. A drop of tetracaine (0.5%) was administered to
each eye just before testing. Minimal clonic seizures are
characterized by rhythmic face and forelimb clonus, rearing and
falling and ventral neck flexion. Minimal tonic hindlimb extension
seizures are characterized by a tonic–clonic flexion–extension
sequence that starts with tonic forelimb extension, followed by
hindlimb flexion, and terminates in full tonic hindlimb extension
(180 degrees to the torso) [53].
Individual adult male N5F2 mice were corneally kindled
according to the procedures described by Matagne and Klitgaard
[35]. Briefly, each mouse received a twice-daily corneal stimula-
tion of 3mA for 3 seconds. Prior to each stimulation, a drop of
0.5% tetracaine was applied to the cornea of each mouse to
provide anesthesia and aid electrical conduction. Seizure severity
was ranked according to the Racine scale [54]: 1, jaw chomping
and vibrissae twitching; 2, facial clonus, head nodding, chewing; 3,
unilateral or alternating forelimb clonus; 4, bilateral forelimb
clonus with rearing and falling; 5, generalized clonus with
immediate loss of balance. The kindling procedure was continued
until each mouse displayed at least five consecutive stage 4–5
secondarily generalized seizures. Results obtained for Scn9a-
N641Y homozygous and heterozygous knockin mice were
compared to wild-type littermates and expressed as the average
behavioral seizure score observed for each stimulation, the
number of stimulations required to reach the first stage 4–5
seizure, and the number of stimulations required to reach four
consecutive stage 4–5 seizures, or a fully kindled state.
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